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Abstract
Background: Tuberous Sclerosis Complex (TSC) is an autosomal dominant tumor disorder characterized by the
growth of hamartomas in various organs including the kidney, brain, skin, lungs, and heart. Rapamycin has been
shown to reduce the size of kidney angiomyolipomas associated with TSC; however, tumor regression is
incomplete and kidney angiomyolipomas regrow after cessation of treatment. Mouse models of TSC2 related
tumors are useful for evaluating new approaches to drug therapy for TSC.
Methods: In cohorts of Tsc2
+/- mice, we compared kidney cystadenoma severity in A/J and C57BL/6 mouse strains
at both 9 and 12 months of age. We also investigated age related kidney tumor progression and compared three
different rapamycin treatment schedules in cohorts of A/J Tsc2
+/- mice. In addition, we used nude mice bearing
Tsc2
-/- subcutaneous tumors to evaluate the therapeutic utility of sunitinib, bevacizumab, vincristine, and
asparaginase.
Results: TSC related kidney disease severity is 5-10 fold higher in A/J Tsc2
+/- mice compared with C57BL/6 Tsc2
+/-
mice. Similar to kidney angiomyolipomas associated with TSC, the severity of kidney cystadenomas increases with
age in A/J Tsc2
+/- mice. When rapamycin dosing schedules were compared in A/J Tsc2
+/- cohorts, we observed a
66% reduction in kidney tumor burden in mice treated daily for 4 weeks, an 82% reduction in mice treated daily
for 4 weeks followed by weekly for 8 weeks, and an 81% reduction in mice treated weekly for 12 weeks. In the
Tsc2
-/- subcutaneous tumor mouse model, vincristine is not effective, but angiogenesis inhibitors (sunitinib and
bevacizumab) and asparaginase are effective as single agents. However, these drugs are not as effective as
rapamycin in that they increased median survival only by 24-27%, while rapamycin increased median survival by
173%.
Conclusions: Our results indicate that the A/J Tsc2
+/- mouse model is an improved, higher through-put mouse
model for future TSC preclinical studies. The rapamycin dosing comparison study indicates that the duration of
rapamycin treatment is more important than dose intensity. We also found that angiogenesis inhibitors and
asparaginase reduce tumor growth in a TSC2 tumor mouse model and although these drugs are not as effective
as rapamycin, these drug classes may have some therapeutic potential in the treatment of TSC related tumors.
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Tuberous Sclerosis Complex (TSC) is an autosomal
dominant tumor disorder characterized by the manifes-
tation of hamartomas in various organs including the
kidney, brain, skin, lungs, and heart [1-3]. This multi-
system disorder is fairly common, occurring at a fre-
quency of 1:6000. The morbidity associated with TSC
includes cognitive impairment, seizures, epilepsy, corti-
cal tubers, cardiac rhabdomyomas, facial angiofibromas,
and pulmonary lymphangioleiomyomatosis (LAM).
Additionally, a majority of TSC patients experience
r e n a lm a n i f e s t a t i o n ss u c ha sk i d n e ya n g i o m y o l i p o m a s
and/or kidney cysts. Kidney angiomyolipomas are age
related tumors that occur in 60-80% of older children
and adults with TSC [4,5] and approximately 50% of
women with sporadic LAM [6]. Sporadic LAM is a pro-
gressive pulmonary disorder that is genetically related to
TSC in that somatic mutations in the TSC1 or TSC2
genes have been identified in abnormal lung tissues
from LAM patients [7].
TSC results from the loss of function of one of two
genes, TSC1 or TSC2, whose gene products are hamar-
tin and tuberin, respectively [8,9]. These two gene pro-
ducts form a tumor suppressor complex that functions
to inhibit mTOR activity in a conserved cellular signal-
ing pathway which is responsible for cell proliferation,
protein synthesis, and nutrient uptake [10,11]. The key
proteins in this pathway include PI3K, Akt, TSC1/TSC2,
Rheb, and mTOR. The multiple roles of this important
regulatory pathway have been described in recent
reviews [12-16]. The inhibitory function of the tuberin-
hamartin complex results from tuberin’s GTP-ase activ-
ity on Rheb, which directly regulates mTOR kinase
activity [17]. When conditions are unfavorable for cell
growth and the TSC1/TSC2 complex is functioning
properly, Rheb-GTP is converted to the GDP form and
mTOR kinase activity is decreased. When mutations
occur in TSC1 or TSC2, the hamartin-tuberin complex
is nonfunctional, Rheb-GTP is favored, and mTOR
kinase is constitutively activated causing hyperphosphor-
ylation of the downstream effectors (p70 S6 kinase and
4E-binding protein1) resulting in increased protein
translation, cell growth, proliferation, and survival.
Several TSC genotype-phenotype studies show that
TSC2 disease is both more common and more severe
than TSC1 disease [3,17-19]. The Tsc2
+/- mouse is a
good model for TSC related kidney disease because it is
genetically similar to the majority of those with TSC, it
develops age related kidney tumors (cystadenomas), and
the mTOR pathway defect that occurs in the kidney
tumors of Tsc2
+/- mice is similar to that observed in
human TSC related tumors [20-23]. Nude mice bearing
subcutaneous Tsc2
-/- tumors derived from mouse
embryo fibroblasts are another useful animal model for
TSC related tumors. The Tsc2
-/- subcutaneous tumor
model is a good generic model for TSC-related tumors
because loss of heterozygosity (LOH) has been found in
many TSC-related kidney and brain tumors [21,24,25].
Rapamycin (Rapamune™ or sirolimus, Wyeth, Madi-
son, NJ) is a macrolide antibiotic that acts to inhibit the
mTOR pathway and is FDA approved for use as an
immunosuppressant following organ transplantation
[26]. More recently, two rapamycin analogs (temsiroli-
mus and everolimus) have been approved for the treat-
ment of renal cell carcinoma [27,28]. Rapamycin (and
analogs) have been shown to restore disregulated
mTOR signaling in cells with abnormal TSC1 and/or
TSC2 and to successfully treat kidney lesions in the
Tsc2
+/- mouse model along with other rodent models
[20,21,29-31]. Furthermore, in early clinical trials evalu-
ating the utility of rapamycin for the treatment of kid-
ney angiomyolipomas associated with TSC and/or LAM,
partial tumor regression has been observed in the
majority of cases. Because responses are incomplete, not
all tumors respond to drug therapy, and patients experi-
ence kidney angiomyolipoma regrowth after cessation of
treatment [32-34], further studies are needed to evaluate
longer duration mTOR inhibitor treatment and also to
identify other active drugs.
There is evidence that other drug classes, such as
those that alter amino acid metabolism, inhibitors of
VEGF signaling, and microtubule inhibitors may be use-
ful in treating TSC. The presence or absence of amino
acids is an important regulator of mTOR signaling [35].
L-Asparaginase is an enzyme that catalyzes the hydroly-
sis of L-asparagine to L-aspartic acid and is used as part
of the curative combination chemotherapy regimen for
the treatment of acute lymphoblastic leukemia (ALL)
[36]. The anti-tumor effect of L-asparaginase is attribu-
ted to the depletion of the L-asparagine, but since some
preparations have glutaminase activity, glutamine may
also be depleted depending on the source of L-asparagi-
nase. It has been shown that human leukemic cells trea-
ted with L-asparaginase have reduced levels of the
mTOR pathway’s targets p70 S6 kinase (p70
s6k) and 4E-
binding protein 1 (4E-BP1) [37]. Furthermore, there are
tissue specific changes in mTOR pathway inhibition and
cellular stress response signals in mice treated with L-
asparaginase [38]. Due to its inhibitory effects on growth
of malignant cells and mTOR pathway activity in some
tissues, L-asparaginase may be useful in treating TSC
related tumors.
Vascular endothelial growth factor (VEGF) signaling is
thought to play an important role in the pathogenesis of
TSC and LAM. Since the brain, skin, and kidney tumors
associated with TSC are vascular [39] and TSC2 loss is
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cultured cells [40], VEGF is a potential target for TSC
treatment. Furthermore, recent studies have shown that
serum VEGF-D levels are elevated in patients with
sporadic or TSC-associated LAM compared with healthy
controls and patients with other pulmonary ailments
[41-43]. The importance of VEGF signaling in the
pathogenesis of TSC suggests that VEGF inhibitors as
single agents or in combination with mTOR inhibitors
may provide a promising treatment. Sorafenib (also
known as BAY 43-9006 and Nexavar) is an oral multi-
targeted kinase inhibitor that blocks vascular endothelial
growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3,
the RAF/Mek/Erk pathway, PDGFR, FLT-3, and C-KIT
[44,45]. It is FDA approved for the treatment of
advanced renal cell and hepatocellular carcinoma
[46,47]. We have previously shown that the combination
of sorafenib plus rapamycin is more effective than single
agents in TSC tumor preclinical studies (Lee et al.,
2009), but have not tested other VEGF signaling path-
way inhibitors. Sunitinib (also known as SU11248 and
Sutent) is a receptor tyrosine kinase inhibitor that tar-
gets both VEGF-R and platelet derived growth factor
receptor (PDGF-R). Sunitinib has been shown to
increase response and survival in patients with meta-
static renal cell carcinoma (RCC) [48] and is also
approved for the treatment of gastrointestinal stromal
tumors [49]. Bevacizumab (also known as rhMAb-VEGF
and Avastin) is a recombinant humanized monoclonal
antibody that binds all human VEGF isoforms and is
approved for the treatment of colon, breast, non-small
cell lung cancer, and glioblastoma [50-54] and also pro-
longs the time to progression of disease in metastatic
RCC [55,56]. The inhibitory effects of sunitinib and bev-
acizumab on VEGF signaling suggest that they may be
useful in the treatment of TSC-related tumors.
Recent studies have shown that the TSC1/TSC2 com-
plex may be important for microtubule-dependent pro-
tein transport because microtubule distribution and
protein transport are disrupted in cells lacking Tsc1 or
Tsc2. [57]. This raises the possibility that microtubule
inhibitors may have useful anti-tumor activity for TSC
related tumors. Vincristine is an anti-neoplastic micro-
tubule inhibitor that binds tubulin dimers to arrest
rapidly dividing cells in metaphase [58,59]. It is used in
combination with other drugs in the treatment of lym-
phoma and leukemia. The defects in microtubule orga-
nization and function observed in Tsc1 and Tsc2 null
cells suggests they may be sensitive to vincristine or
other microtubule inhibitors.
In order to identify novel approaches for the treat-
ment of tumors associated with TSC, we used two mod-
els of TSC related tumors in a series of preclinical
studies. Tsc2
+/- mice were used to compare disease
severity of kidney disease in two different mouse strains
(C57BL/6 and A/J), evaluate the age related progression
of kidney disease (in A/J mice), and compare three dif-
ferent dosing schedules of rapamycin (daily, daily plus
weekly, and weekly). We used a subcutaneous Tsc2
-/-
tumor model to evaluate the efficacy of two VEGF inhi-
bitors (sunitinib and bevacizumab), asparaginase, and a
microtubule inhibitor (vincristine).
Methods
Baseline tumor burden for untreated A/J versus C57BL/6
Tsc2
+/- mice and age related kidney disease in A/J Tsc2
+/-
mice
The Tsc2
+/- mouse is heterozygous for a deletion of
exons 1-2 as previously described [60]. In order to
determine the baseline tumor burden for untreated Tsc2
+/- in the A/J and C57BL/6 backgrounds, strain specific
colonies of each background were created. Strain speci-
fic colonies were created for both the A/J and C57BL/6
background by backcrossing female Tsc2 heterozygous
offspring with their pure strain Tsc2 wildtype fathers
until the N5 generation was reached. Mice from the N5
generations were assigned to cohorts based on age, gen-
der, and genotype. The cohorts were: Tsc2
+/- 9m o n t h s
consisting of 8 males and 8 females, Tsc2
+/+ 9m o n t h s
consisting of 2 males and 2 females, Tsc2
+/- 12 months
consisting of 4 males and 4 females, and Tsc2
+/+ 12
months consisting of 2 males and 2 females. To deter-
mine the age related kidney disease in the A/J back-
ground, A/J Tsc2
+/- mice were assigned to three
additional cohorts. The cohorts were: A/J Tsc2
+/- 3
months, A/J Tsc2
+/- 5m o n t h s ,a n dA / JTsc2
+/- 7
months. Each cohort contained 4 mice.
Mice were sacrificed according to age and cohort
assignment. Upon sacrifice, kidneys, livers, and lungs
were examined. All animals in Tsc2
+/- cohorts had gross
kidney lesions. There were no obvious liver tumors.
Three A/J Tsc2
+/- animals had gross lung abnormalities
(1 in the untreated 3 month cohort, and 2 in the cohort
treated with weekly rapamycin × 12 weeks) and one
mouse, from the cohort treated with weekly rapamycin
× 12 weeks, had a superficial tail tumor. Since non-kid-
ney tumors were rare events, these were not studied
further. We also looked at Tsc2
+/+ cohorts at nine and
twelve months of age and observed no gross or micro-
scopic kidney lesions.
Quantification of kidney cystadenomas in Tsc2
+/- mice
For histological quantification of kidney cystadenomas,
each kidney was prepared as previously described [61].
All cystadenomas were counted, measured, and scored
according to the scale shown in Additional File 1 by a
blinded researcher (CW or AN). Since the kidney cysta-
denomas of these Tsc2
+/- mice can be divided into the
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lesions, we use “kidney cystadenomas” to refer to the
entire spectrum of kidney lesions observed. In addition
to analyzing data according to all cystadenomas, a sub-
group analysis was also done by coding cystic, pre-papil-
lary, papillary, and solid kidney lesions separately. The
scale used to define cystadenoma subtypes is shown in
Additional File 2.
Rapamycin dosing schedules in A/J Tsc2
+/- mice
A/J Tsc2
+/- mice were assigned to one of three different
rapamycin treatment cohorts (Groups 1-3) or an
untreated control group (Group 4). The rapamycin
cohorts included the following schedules: daily × 4
weeks plus weekly × 8 weeks (Group 1), daily × 4 weeks
(Group 2), weekly × 12 weeks (Group 3). All animals
started treatment at nine months of age and were eutha-
nized twelve weeks later. Mice in Group 1 were treated
with 8 mg/kg rapamycin administered by intraperitoneal
injection (IP) Monday through Friday for four weeks fol-
l o w e db yw e e k l yd o s e so f8m g / k gr a p a m y c i nI Pf o r
eight weeks. Mice in Group 2 were treated with 8 mg/
kg rapamycin IP Monday through Friday for four weeks
and received no drug treatment for the next 8 weeks.
Mice in Group 3 were treated with weekly 8 mg/kg
rapamycin IP for twelve weeks. Rapamycin powder was
obtained from LC Laboratories (Woburn, MA) and a 20
mg/ml stock of rapamycin was made in ethanol (stored
at -20°C for up to one week). The stock solution was
diluted to 1.2 mg/ml in vehicle (0.25% PEG, 0.25%
Tween-80) for the 8 mg/kg dose. Rapamycin treatments
were administered within two hours of their prepara-
tion. All animals were checked daily (5 days per week),
and general health and behavior were noted. All rapa-
mycin treated animals were weighed at 9 months (at the
start of rapamycin treatment), and again at the time of
euthanasia at ~12 months (see Additional File 3). All
mice were euthanized at approximately twelve months
of age according to institutional animal care guidelines.
The severity of kidney disease was calculated using
quantitative histopathology as described previously.
Untreated A/J Tsc2
+/- mice from the 9 month and 12
month cohorts were weighed at the time of necropsy for
comparison. All experiments were done according to
animal protocols approved by our institutional animal
protocol review committee (Children’s Hospital Boston,
Boston, MA) and were compliant with federal, local, and
institutional guidelines on the care of experimental
animals.
Treatment of subcutaneous tumors with asparaginase,
vincristine, sunitinib, bevacizumab, and rapamycin
Nude mice (strain CD-1nuBR, up to 6-8 weeks old)
were obtained from Charles River Laboratories, Inc.
(Wilmington, Massachusetts) and injected subcuta-
neously on the dorsal flank with 2.5 million NTC/
T2null (Tsc2
-/-,T r p 5 3
-/-) cells. NTC/T2null cells are
mouse embryonic fibroblasts that have been described
previously [21]. A total of 80 CD-1 nude mice were
divided into 10 randomly assigned groups: untreated
control group, single agent rapamycin, single agent
asparaginase, combination asparaginase plus rapamycin,
single agent vincristine, combination vincristine plus
rapamycin, single agent sunitinib, combination sunitinib
plus rapamycin, single agent bevacizumab, and combina-
t i o nb e v a c i z u m a bp l u sr a p a m y c i n .A ss o o na st u m o r s
became visible, they were measured Monday through
Friday using calipers. Tumor volumes were calculated
using the formula: length × width × width × 0.5. All
mice began treatment when tumors reached a volume
of ~100 mm
3. All mice were euthanized once tumors
reached ~3000 mm
3 in accordance with institutional
animal care guidelines.
Untreated mice did not receive any treatment even
after tumors reached a volume ≥ 100 mm
3. Rapamycin
treated groups received 200 μlo fa1 . 2m g / m ls o l u t i o n
of rapamycin (8 mg/kg) three times per week (on
Mondays, Wednesdays, and Fridays) by IP injection.
Doses of asparaginase, vincristine, sunitinib, and beva-
cizumab were selected based on anti-tumor activity in
published preclinical studies [38,62-64]. Asparaginase
treated groups received 200 μl of a 300 IU/mL solution
of asparaginase on Mondays and Thursdays for 4
weeks by IP injection. Vincristine treated groups
received 200 μlo fa0 . 0 7 5m g / m Ls o l u t i o no fv i n c r i s -
tine once per week for four weeks by IP injection.
Sunitinib treated groups received 200 μlo fa1 2m g /
mL solution of sunitinib daily (Monday-Friday) by
gavage. Bevacizumab treated groups received 200 μlo f
0.75 mg/mL solution of bevacizumab once every two
weeks by IP injection. All drug doses were calculated
assuming a weight of 30 g per mouse. Asparaginase
powder was obtained from the Brigham and Women’s
Hospital Research Pharmacy (Boston, MA) and diluted
in sterile PBS. Vincristine was obtained in a 1 mg/mL
solution from the Brigham and Women’sH o s p i t a l
Research Pharmacy (Boston, MA) and diluted in sterile
PBS. Bevacizumab was obtained in a 25 mg/mL solu-
tion from the Brigham and Women’sH o s p i t a l
Research Pharmacy (Boston, MA) and diluted in sterile
phosphate buffered saline (PBS). Sunitinib powder was
obtained from LC Laboratories (Woburn, MA) and
diluted in a sterile 5% glucose solution. Rapamycin
powder was obtained from LC Laboratories (Woburn,
MA) and a 20 mg/mL stock of rapamycin was made in
ethanol (stored at -20°C for up to one week). The
stock solution was diluted to 1.2 mg/mL in vehicle
(0.25% PEG-400, 0.25% Tween-80).
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animals were weighed at the start of the study and at
the time of necropsy. Six animals had to be euthanized
early due to dehydration and weight loss (Additional
File 4). The survival and tumor growth data for these
animals were included in all analyses. All mice from
rapamycin treated cohorts were euthanized 24 hours
after the last rapamycin treatment upon reaching the
endpoint tumor volume. Upon sacrifice, whole blood
was obtained for drug level testing.
Whole blood rapamycin levels
Whole blood rapamycin levels were measured from a
subset of animals treated with rapamycin in the nude
mouse treatment studies described above. Blood was
removed at necropsy 24 hours after the final treatment
of rapamycin. Whole blood was obtained through car-
diac puncture, dispensed into an EDTA-containing
blood collection tube, and diluted with an equal volume
of sterile PBS to ensure sufficient volume for rapamycin
level analysis. All measured rapamycin levels were cor-
rected according to sample dilution at time of analysis.
Only bevacizumab plus rapamycin, sunitinib plus rapa-
mycin and single agent rapamycin cohorts could be ana-
lyzed for rapamycin levels due to treatment schedules.
Whole blood samples were tested for rapamycin levels
at the Clinical Laboratory at Children’s Hospital Boston
(Boston, Massachusetts). The range of detection is 0.5
to 100 ng/ml of rapamycin.
Statistical analyses
GraphPad Prism software (version 4.01) was used for all
data analysis, with a p-value ≤ 0.05 indicating statistical
significance. All calculations were completed from raw
data by two researchers (AN and CW). A standard
unpaired t test was used to test all quantitative data,
and the Mantel-Cox logrank analysis was used for survi-
val data.
Results
Kidney tumor severity is age related and increased in A/J
Tsc2
+/- mice compared with C57BL/6 Tsc2
+/- mice
In order to compare kidney disease severity in different
Tsc2
+/- mouse strains, we evaluated kidney cystadeno-
mas in cohorts of A/J and C57BL/6 Tsc2
+/- mice at nine
and twelve months of age. Kidney disease severity for all
cohorts is shown in Figure 1 and Table 1. Untreated A/J
cohorts are shown in green, and untreated C57BL/6
cohorts are shown in blue. Although data are shown as
both average cystadenoma score per kidney (Figure 1a)
and average number of cystadenomas per kidney (Figure
1b), these have a similar trend. The average score per
kidney for the A/J Tsc2
+/- untreated 12 m cohort
(120.20 ± 52.53) is significantly greater (p < 0.0001)
than that of the C57BL/6 Tsc2
+/- untreated 12 m cohort
(15.19 ± 9.39). Similarly, the average score per kidney
for the A/J Tsc2
+/- untreated 9 m cohort (74.47 ± 23.07)
is significantly greater (p < 0.0001) than that of the
C57BL/6 Tsc2
+/- untreated 9 m cohort (7.97 ± 4.76).
Interestingly, the average score per kidney for the
A/J Tsc2
+/- untreated 9 m cohort is significantly greater
(p < 0.0001) than that of the C57BL/6 Tsc2
+/- untreated
12 m cohort. Since A/J Tsc2
+/- mice have a higher aver-
a g es c o r ep e rk i d n e ya tn i n em o n t h so fa g et h a n
C57BL/6 Tsc2
+/- mice at 12 months of age, these data
show that the A/J Tsc2
+/- strain has a significantly
higher tumor burden than the C57BL/6 Tsc2
+/- strain.
There is no significant difference in severity of kidney
disease between males and females within the same
strain (see Additional File 5). This is true for both A/J
Tsc2
+/- mice and C57BL/6 Tsc2
+/- mice at 9 months of
age and 12 months of age.
From previous studies, we have shown that the severity
of kidney disease increases with age in C57BL/6 Tsc2
+/-
mice [20]. In order to understand the progression of
kidney tumor growth in A/J Tsc2
+/- mice, data was col-
lected at different time points. The average score per
kidney for the A/J Tsc2
+/- mice at 3 months, 5 months,
and 7 months of age was 6.5, 33.0, and 57.7, respec-
tively. It is important to note that the score per kidney
for the A/J Tsc2
+/- untreated 5 m cohort (33.00 ± 13.53)
is significantly greater (p = 0.0010) than that of the
C57BL/6 Tsc2
+/- untreated 12 m cohort (15.19 ± 9.39).
These data further confirm that the A/J Tsc2
+/- strain
develops more severe kidney disease than the C57BL/6
Tsc2
+/- strain and will allow for higher through-put Tsc2
+/- preclinical studies.
Comparison of three rapamycin dosing schedules
in Tsc2
+/- mice
In a prior preclinical study, we determined that daily
rapamycin treatment for two months combined with a
rapamycin maintenance dose once a week for five
months dramatically reduced tumor burden by 94.5% as
compared to the untreated control [61]. However,
because that study included only one single agent rapa-
mycin treatment group in which animals were treated
daily × 1 month, then weekly × 4 months, then daily ×
1 month, we do not clearly understand the impact of
weekly rapamycin treatment. In order to further evaluate
the efficacy of rapamycin weekly maintenance dosing,
here we compared three rapamycin dosing schedules in
A/J Tsc2
+/- mice (weekly, daily, daily plus weekly). All
animals started treatment at 9 months of age and were
euthanized 12 weeks after treatment started. As shown
in Table 1 and Figure 1, all three treatment cohorts
showed a significant decrease in the average cystade-
noma score per kidney as compared to both the
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+/- untreated control
groups (number of cystadenomas gave similar trends).
Additionally, rapamycin dosed daily × 4 weeks followed
by weekly × 8 weeks (Group 1, score per kidney 21.5)
was more effective than rapamycin dosed daily × 4
weeks with no weekly maintenance dosing (Group 2,
score per kidney 41.1, p = 0.007).
This data indicates that there was some tumor
regrowth during the 8 weeks off of treatment in Group
2. Interestingly, dosing rapamycin weekly × 12 weeks
(Group 3, score per kidney 22.6) was equally effective
compared with dosing rapamycin daily × 4 weeks plus
weekly × 8 weeks (Group 1). This suggests that the
duration of rapamycin exposure is the critical factor and
d o s ei n t e n s i t yi sl e s si m p o r t a n ta st h e r ew a sn ob e n e f i t
to giving the higher doses for the first 4 weeks in Group
1. According to drug level testing in whole blood for
this and prior preclinical studies [20,65], average rapa-
mycin levels in whole blood are ~12-40 ng/ml from 24
hours to 6 days, and ~6 ng/ml on days 7-8 after a single
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Figure 1 A/J strain Tsc2
+/- mice show an increased severity of kidney disease with age, a greater kidney tumor burden than C57BL/6
Tsc2
+/- mice, and best response to longer duration rapamycin treatment. The average score per kidney for each cohort is shown in 1a.
The average number of cystadenomas per kidney for each cohort is shown in 1b. The red p-values indicate a statistically significant difference
(p < 0.05) between the two cohorts being compared. These data show a significant increase in both the score per kidney and the number of
cystadenomas per kidney in the A/J strain as compared to the C57BL/6 strain for both 9 months of age and 12 months of age. Additionally,
these data show a significant increase with age in both the score per kidney and the number of cystadenomas per kidney for the A/J Tsc2
+/-
strain. Furthermore, the tumor burden is reduced with rapamycin therapy with the weekly × 12 weeks cohort and the daily × 4 weeks plus
weekly × 8 weeks cohort showing the most reduction. This data is summarized in Table 1.
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ing in mice correlates well with clinical dosing in
humans for which the typical range for target trough
(24 hour) levels is 3-20 ng/ml.
Kidney cystadenoma subtypes are similar in A/J and
C57BL/6 cohorts and shift to more pre-papillary and
cystic lesions with rapamycin treatment
We determined kidney cystadenoma subtypes for all A/J
and C57BL/6 cohorts. The total score per kidney cate-
gorized by each cystadenoma subtype is shown in Figure
2a, and the percent contribution to total score per kid-
ney for each cystadenoma subtype is shown in Figure 2b
and Table 2. For all of the A/J and C57BL/6 untreated
cohorts, papillary lesions contributed the greatest per-
centage to total score per kidney while cystic and solid
lesions account for the smallest percentage. Papillary
lesions made up 53-62% of the total score per kidney
for the A/J untreated cohorts and 43-46% for the
C57BL/6 untreated cohorts. Cystic lesions made up 5-
12% of the total score per kidney for the A/J untreated
cohorts and 9-13% for the C57BL/6 untreated cohorts.
Pre-papillary lesions contributed 17-24% to the total
score per kidney for the A/J untreated cohorts and 26-
34% for the C57BL/6 untreated cohorts. Solid lesions
contributed 7-14% to the total score per kidney for the
A/J untreated cohorts and 9-14% for the C57BL/6
untreated cohorts. Compared to the untreated control
cohorts, all rapamycin treatment cohorts showed a
lower percentage of papillary (13-23%) and solid (0-1%)
lesions and a higher percentage of cystic (18-31%) and
pre-papillary (51-66%) lesions. These data suggest that
rapamycin treatment may cause a shift from solid and
papillary cystadenomas to cystic and pre-papillary
cystadenomas.
Treatment of Tsc2
-/- subcutaneous tumors with
angiogenesis inhibitors, asparaginase, and vincristine
In order to evaluate the utility of some novel drug
classes for the treatment of TSC related tumors, we
investigated the efficacy of asparaginase, sunitinib, beva-
cizumab, and vincristine in treating a relevant subcuta-
neous tumor model. We used nude mice bearing
subcutaneous Tsc2
-/- tumors derived from NTC/T2 null
cells in a preclinical study with the following cohorts:
untreated, rapamycin treated, asparaginase treated,
asparaginase plus rapamycin combination treated, vin-
cristine treated, vincristine plus rapamycin combination
treated, sunitinib treated, sunitinib plus rapamycin trea-
ted, bevacizumab treated, and bevacizumab plus rapa-
mycin treated. Average tumor growth for each cohort is
shown in Figures 3a, 4a, 5a, 6a, and Table 3. The data
points represent days when at least four mice of the
treatment group had tumors measured. Tumor volumes
for single agents were compared to untreated controls
on day 30 for all groups except vincristine because this
was the last day with at least four data points for the
untreated group; day 23 was used for vincristine (last
Table 1 Average Score and Number of Cystadenomas per Kidney for A/J and C57BL/6 Tsc2
+/- Cohorts
Tsc2
+/- Cohort
(strain, treatment, age)
Score per Kidney
(ave ± std dev)
Number per
Kidney
(ave ± std dev)
% Reduction in
Score per Kidney
vs. Group 4
n Group
Number
Number of
Rapa Doses
Duration of
Treatment
Total Dose
per Mouse
(mg)
C57BL/6, untreated, 12
months
15.19 ± 9.39 5.94 ± 2.79 8
A/J, untreated, 3 months 6.50 ± 4.60 4.00 ± 1.69 4
A/J, untreated, 5 months 33.00 ± 13.53 13.00 ± 4.28 4
A/J, untreated, 7 months 57.75 ± 18.24 22.50 ± 5.88 4
A/J, untreated, 9 months 74.47 ± 23.07 22.63 ± 6.66 16
**A/J, untreated, 12
months
120.20 ± 52.53 35.25 ± 14.22 8 4
Group 1
*A/J rapa daily × 4 weeks
then weekly × 8 weeks
21.50 ± 8.38 7.38 ± 2.83 82% 8 1 28 12 weeks 6.72
Group 2
*A/J rapa daily × 4 weeks
41.13 ± 25.33 13.25 ± 6.32 66% 8 2 20 4 weeks 4.8
Group 3
*A/J rapa weekly × 12
weeks
22.61 ± 9.89 8.17 ± 3.07 81% 9 3 12 12 weeks 2.88
* All treatments started at 9 months of age, and mice were euthanized 12 weeks later (at ~12 months of age)
** Untreated controls were euthanized at 12 months of age
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Page 7 of 18Table 2 Distribution of Kidney Lesion Subtype for A/J and C57BL/6 Tsc2
+/- Cohorts
% of Total Score per Kidney
Tsc2
+/- Cohort (strain, treatment, age) Cyst Pre-papillary Papillary Solid
C57BL/6, untreated, 9 months 13.34 26.67 45.88 14.11
C57BL/6, untreated, 12 months 8.64 34.15 43.21 8.64
A/J, untreated, 3 months 11.54 19.23 57.69 11.54
A/J, untreated, 5 months 9.47 21.59 62.12 6.82
A/J, untreated, 7 months 4.98 23.6 60.17 11.26
A/J, untreated, 9 months 12.38 21.27 53.63 12.51
A/J, untreated, 12 months 11.18 16.75 59.07 13.52
Group 1
A/J rapa daily × 4 weeks then weekly × 8 weeks
31.4 51.44 14.83 0.87
Group 2
A/J rapa daily × 4 weeks
18.08 58.67 22.64 0.91
Group 3
A/J rapa weekly × 12 weeks
20.88 65.86 13.02 0.25
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Figure 2 Rapamycin treated Tsc2
+/- mice show a higher percentage of cystic and pre-papillary cystadenomas and a smaller
percentage of papillary and solid cystadenomas. The absolute score per kidney for each cystadenoma subtype is shown in Figure 2a, and
the percent of total score per kidney for each cystadenoma subtype is shown in Figure 2b. For a description of each subtype, see Additional File
2. Papillary cystadenomas contribute the largest percentage to total score per kidney in untreated A/J and C57BL/6 cohorts at all time points.
Pre-papillary cystadenomas contribute the largest percentage to total score per kidney in A/J cohorts treated with rapamycin. Treatment with
rapamycin results in a decrease in the percentages of papillary and solid cystadenomas and an increase in the percentages of pre-papillary and
cystic cystadenomas.
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Figure 3 Asparaginase treatment improved survival and decreased tumor growth in nude mice bearing Tsc2
-/- tumors. (a) Average
tumor volume over time for asparaginase and asparaginase plus rapamycin treated animals. (b) Survival curve for indicated treatment cohorts.
Based on survival analysis and comparison of tumor volumes on day 30, asparaginase improves survival and decreases tumor growth compared
to the untreated cohort. Asparaginase is not as effective as single agent rapamycin in improving survival or decreasing tumor growth. Based on
analysis and comparisons of tumor volumes on day 65, asparaginase in combination with rapamycin provided no improvement over single
agent rapamycin treatment.
Figure 4 Sunitinib treatment improved survival in nude mice bearing Tsc2
-/- tumors. (a) Average tumor volume over time for sunitinib and
sunitinib plus rapamycin treated animals. (b) Survival curve for indicated treatment cohorts. Based on survival analysis and comparison of tumor
volumes on day 30, sunitinib improves survival but does not decrease tumor growth compared to the untreated cohort. Sunitinib is not as
effective as single agent rapamycin in improving survival or decreasing tumor growth. Based on analysis and comparisons of tumor volumes on
day 65, sunitinib in combination with rapamycin provided no improvement over single agent rapamycin treatment.
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Page 9 of 18Figure 5 Bevacizumab treatment improved survival and decreased tumor growth in nude mice bearing Tsc2
-/- tumors. (a) Average
tumor volume over time for bevacizumab and bevacizumab plus rapamycin treated animals. (b) Survival curve for indicated treatment cohorts.
Based on survival analysis and comparison of tumor volumes on day 30, bevacizumab improves survival and decreases tumor growth compared
to the untreated cohort. Bevacizumab is not as effective as single agent rapamycin in improving survival or decreasing tumor growth. Based on
analysis and comparisons of tumor volumes on day 65, bevacizumab in combination with rapamycin provided no improvement over single
agent rapamycin treatment.
Figure 6 Vincristine does not decrease tumor growth or increase survival in nude mice bearing Tsc2
-/- tumors. (a) Average tumor
growth over time for vincristine and vincristine plus rapamycin treated animals. (b) Survival curve for indicated cohorts. Based on survival
analysis and comparison of tumor volumes on days 23 and 65, vincristine was not effective as a single agent or in combination with rapamycin.
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Page 11 of 18day with at least four data points). Tumor volumes for
combination treatments were compared to single agent
rapamycin treatment on day 65 because this was the last
day with at least four data points for all combination
treatment groups. Survival curves for each cohort are
shown in Figures 3b, 4b, 5b, and 6b. Survival curves
were compared using the Mantel Cox logrank analysis.
Single agent asparaginase improves survival and
reduces Tsc2
-/- tumor growth. The day 30 average
tumor volume for the asparaginase cohort (1978 ± 167
mm
3) and the untreated cohort (2618 ± 187 mm
3)a r e
significantly different (p = 0.0405). The average tumor
volumes at day 65 for the asparaginase plus rapamycin
cohort (1570 ± 378 mm
3) and the rapamycin cohort
(1349 ± 302 mm
3) are similar (Figure 3a, Table 3). The
median survival of the single agent asparaginase cohort
(39.5 days) and the median survival of the untreated
cohort (31 days) are significantly different (p = 0.0101).
However, the median survival of the asparaginase plus
rapamycin treated cohort (71 days) is not significantly
different than the median survival of the single agent
rapamycin treated cohort (84.5 days, Figure 3b, Table
3). The slightly lower median survival in the asparagi-
nase plus rapamycin combination group suggests that
adding asparaginase to rapamycin may enhance tumor
growth in some cases, although the mechanism is not
known. In summary, asparaginase as a single agent is
effective at reducing tumor growth and increasing survi-
val when compared to the untreated cohort. Single
agent asparaginase is not as effective as rapamycin at
decreasing tumor volume or increasing survival.
Furthermore, adding asparaginase to rapamycin did not
reduce disease severity when compared to single agent
rapamycin.
Single agent sunitinib improves survival in mice bear-
ing Tsc2
-/- tumors. The day 30 average tumor volume for
the sunitinib cohort (1886 ± 287 mm
3) was smaller than
that of the untreated cohort (2618 ± 187 mm
3), but this
difference was not statistically significant. The average
tumor volumes at day 65 for the sunitinib plus rapamycin
cohort (1643 ± 246 mm
3) and the rapamycin cohort
( 1 3 4 9±3 0 2m m
3) are similar (Figure 4a, Table 3). The
median survival of the single agent sunitinib cohort (39
days) and the median survival of the untreated cohort (31
days) are significantly different (0.0193). However, the
median survival of the sunitinib plus rapamycin treated
cohort (80 days) is not significantly different than the
median survival of the single agent rapamycin treated
cohort (84.5 days, Figure 4b, Table 3). In summary, suni-
tinib as a single agent is effective at increasing survival,
but not at reducing tumor growth, when compared to
the untreated cohort. Single agent sunitinib is not as
effective as rapamycin at decreasing tumor volume or
increasing survival. Furthermore, adding sunitinib to
rapamycin did not reduce disease severity when com-
pared to single agent rapamycin.
Single agent bevacizumab improves survival and
reduces Tsc2
-/- tumor growth. The day 30 average
tumor volume for the bevacizumab cohort (1233 ± 366
mm
3) and the untreated cohort (2618 ± 187 mm
3)a r e
significantly different (p = 0.0172). The average tumor
volumes at day 65 for the bevacizumab plus rapamycin
cohort (1652 ± 557 mm
3) and the rapamycin cohort
(1349 ± 302 mm
3) are similar (Figure 5a, Table 3). The
median survival of the single agent bevacizumab cohort
(38.5 days) and the median survival of the untreated
cohort (31 days) are significantly different (p value =
0.0131). However, the median survival of the bevacizu-
mab plus rapamycin treated cohort (60 days) is not sig-
nificantly different than the median survival of the
single agent rapamycin treated cohort (84.5 days, Figure
5b, Table 3). The slightly lower median survival in the
bevacizumab plus rapamycin combination group sug-
gests that adding bevacizumab to rapamycin may
enhance tumor growth in some cases, although the
mechanism is not known. In summary, bevacizumab as
a single agent is effective at reducing tumor growth and
increasing survival when compared to the untreated
cohort. Single agent bevacizumab is not as effective as
rapamycin at decreasing tumor volume or increasing
survival. Furthermore, adding bevacizumab to rapamycin
did not reduce disease severity when compared to single
agent rapamycin.
V i n c r i s t i n ew a sn o te f f e c t i v ef o rt h et r e a t m e n to f
Tsc2
-/- tumors. The day 23 average tumor volume for
the vincristine cohort (2289 ± 242 mm
3)a n dt h e
untreated cohort (1557 ± 260 mm
3) are not significantly
different. The average tumor volumes at day 65 for the
vincristine plus rapamycin cohort (2050 ± 384 mm
3 and
the rapamycin cohort (1349 ± 302 mm
3) are similar.
(Figure 6a, Table 3). Survival data shows that the med-
ian survival of the single agent vincristine cohort (26
days) does not differ significantly from the median sur-
vival of the untreated cohort (31 days). The median sur-
vival of the vincristine plus rapamycin treated cohort
(77 days) is also not significantly different than the med-
ian survival of the single agent rapamycin treated cohort
(84.5 days, Figure 6b, Table 3). In summary, vincristine
a sas i n g l ea g e n ti sn o te f f e c t i v ea tr e d u c i n gt u m o r
growth and increasing survival when compared to the
untreated cohort or the single agent rapamycin cohort.
Furthermore, adding vincristine to rapamycin did not
reduce disease severity when compared to single agent
rapamycin.
Rapamycin drug levels in combination treated animals
Rapamycin is metabolized by CYP3A4 therefore drug
levels can vary when there is exposure to other drugs
Woodrum et al. Journal of Translational Medicine 2010, 8:14
http://www.translational-medicine.com/content/8/1/14
Page 12 of 18that either induce or inhibit CYP3A4. To be sure there
were no significant drug interaction issues in our stu-
dies, rapamycin levels were measured in tumors or
whole blood 24 hours after the last dose in a subset of
animals from our studies (Additional File 6). Average
blood rapamycin levels in the sunitinib plus rapamycin
group (137.9 ± 29.23 ng/ml), bevacizumab plus rapamy-
cin group (94 ± 34.4 ng/ml), and the single agent rapa-
mycin group (86.4 ± 0.86 ng/ml) were not statistically
different. Rapamycin levels for the asparaginase plus
rapamycin and vincristine plus rapamycin cohorts are
not reported due to the treatment schedules of asparagi-
nase and vincristine. Asparaginase and vincristine treat-
ments were given for only 4 weeks and so had not been
administered to mice in these cohorts for several weeks
prior to the last dose of rapamycin. Based on drug level
testing, we conclude that sunitinib and bevacizumab did
not significantly affect the metabolism of rapamycin in
the preclinical studies reported here.
Rapamycin treatment associated with lack of weight gain
in nude mice bearing Tsc2
-/- tumors
Six rapamycin treated nude mice bearing Tsc2
-/- subcu-
taneous tumors required early euthanasia. The six mice
presented with hunched posture, dehydration, and
weight loss, and were euthanized per protocol standards.
Each of the six mice belonged to different treatment
cohorts; however, all of the mice received rapamycin
treatment (Additional File 4). Because nude mice are
immunodeficient and rapamycin is an immunosuppres-
sant drug, these animals may be at higher risk for rapa-
mycin toxicity. These toxicities prompted further review,
as they have not been observed in our prior studies. As
shown in Additional File 7, we noted a lack of weight
gain in nude mouse cohorts treated with rapamycin.
These toxicities also prompted a comparison of weights
before and after treatment in our A/J Tsc2
+/- experi-
ment; there was no significant difference in weights
before and after treatment in the rapamycin treated
cohorts and there was no difference in the average
weights of the untreated 9 month and 12 month cohorts
(see Additional File 3). Although the average weight of
one of the rapamycin treated cohorts (Group 2, rapamy-
cin treated daily × 4 weeks) was lower than the
untreated group at 12 months (Group 4), the difference
was small. We did not observe any increased mortality
in the rapamycin treated Tsc2
+/- cohorts.
Discussion
The Tsc2
+/- mouse is an excellent mouse model for the
s t u d yo fT S Cr e l a t e dk i d n e yd i s e a s e .W eh a v ep r e v i o u s l y
used Tsc2
+/- mice in a C57BL/6 mixed strain to show
that mTOR inhibitor treatment reduces kidney tumor
severity, to investigate the timing of mTOR inhibitor
treatment, and to show that addition of prolonged weekly
maintenance rapamycin treatment was extremely effec-
tive [20,21,61]. However, a major disadvantage of the
Tsc2
+/- mouse model in a predominantly C57BL/6 back-
ground is that kidney disease develops gradually so pre-
clinical studies can take 12-18 months to complete. In
this study, we sought to improve the Tsc2
+/- mouse as a
preclinical model for TSC tumor studies. Based on obser-
vations regarding strain differences reported in Onda et
al. 1999 [60], we backcrossed the Tsc2
+/- genotype onto
A/J and C57BL/6 backgrounds, compared kidney disease
severity, and found that the A/J strain shows a much
higher kidney tumor burden than mice in the C57BL/6
background at 9 and 12 months of age as shown by the
average score per kidney and average number of cystade-
nomas per kidney. Similar to TSC related kidney disease
in humans, the tumor burden increases with age in both
mouse strains. Interestingly, the A/J Tsc2
+/- strain shows
a significantly higher tumor burden at 5 months of age
than the C57BL/6 Tsc2
+/- strain at 12 months of age.
Based on the findings of this study, the A/J strain Tsc2
+/-
mice have a 5-10 fold higher disease burden than C57BL/
6s t r a i nTsc2
+/- mice and are a superior and higher
through-put Tsc2
+/- mouse model for preclinical studies
relevant to TSC kidney disease and tumors. Furthermore,
b e c a u s et h e r ei sad r a m a t i cd ifference in the severity of
the kidney tumor phenotype in these two mouse strains,
they could be used to identify modifier genes that impact
the severity of TSC renal manifestations [66].
The potential utility of rapamycin treatment for a pro-
longed duration was suggested by the results of a pre-
vious preclinical study using C57BL/6 Tsc2
+/- mice in
which we noted that a rapamycin dosing schedule that
included daily treatment for 2 months and weekly treat-
ment for 6 months, resulted in a dramatic 94.5% reduc-
tion in kidney tumor severity [61]. In that study,
rapamycin (IP) was given at a dose of 8 mg/kg Monday
through Friday from 6 to 7 months of age, followed by a
maintenance dose of 16 mg/kg once a week from 7 to
12 months of age, followed by daily rapamycin treat-
ment (8 mg/kg Monday through Friday) from 12 to 13
months of age. We also note that in previous CCI-779
preclinical studies, giving a lower dose over 3 months
seemed to be more effective than a higher dose for 2
months (84% reduction with a total dose of 4.32 mg per
mouse [21] versus 64% reduction with a total dose of
9.6 mg per mouse [20]. These studies suggest that dos-
ing of mTOR inhibitors at a low dose for a prolonged
period of time may be the optimal strategy to maximize
benefit and limit drug toxicity. However, a major limita-
tion in understanding the impact of dose intensity, dura-
tion of therapy, and weekly mTOR inhibitor dosing
based on our prior preclinical studies is that we have
previously compared treatment groups from different
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ences. Because the issue of optimizing rapamycin dosing
to maximize efficacy while limiting toxicity has clinical
implications, here we further investigated the issue of
rapamycin dosing schedule and dose intensity by
directly comparing three different rapamycin treatment
groups (daily × 4 weeks, daily × 4 weeks then weekly ×
8 weeks, and weekly × 12 weeks). We found that opti-
mal treatment correlated with duration of treatment,
not total dose given. There was a 66% reduction with a
total dose of 4.8 mg per mouse in the group treated
daily × 4 weeks, an 82% reduction with a total dose of
6.72 mg per mouse in the group treated daily × 4 weeks
plus weekly × 8 weeks, and an 81% reduction with a
total dose of 2.88 mg per mouse in the group treated
weekly × 12 weeks (see Table 1). These findings demon-
strate that low dose rapamycin treatment for a longer
duration of time is most effective in the Tsc2
+/- mouse,
and it would be reasonable to evaluate this dosing strat-
egy in future TSC clinical trials.
Our findings also clearly demonstrate that the
response of kidney tumors to rapamycin in the Tsc2
+/-
mouse correlates well with observations in early TSC
angiomyolipoma clinical trials. In A/J Tsc2
+/- mice,
cystadenoma score per kidney in untreated animals at 9
months of age is 74.4, and cystadenoma score per kid-
ney is 41.13 in the groups treated daily × 4 weeks, but
21.50 in the group treated daily × 4 weeks then weekly
× 8 weeks (Table 1). Furthermore, the higher kidney
tumor score in the group treated daily × 4 weeks (com-
pared with the group treated daily × 4 weeks then
weekly × 8 weeks) is consistent with tumor regrowth
during months ~10-12 when no drug treatment was
given. This result is analogous to what is observed in
patients with kidney angiomyolipomas associated with
TSC and/or LAM treated with rapamycin. In a cohort
of 20 TSC and/or LAM patients treated with rapamycin
for 12 months and then followed off of treatment at 18
months and 24 months, the average kidney angiomyoli-
poma volume was 71.6 ml at baseline, 36.5 ml at 12
months (~50% size reduction), 64.8 ml at 18 months,
and 74.9 ml at 24 months [34]. In both mice and
humans, TSC related kidney tumors regress during
rapamycin treatment and regrow when rapamycin treat-
ment is stopped. This striking similarity further illus-
trates the clinical relevance of preclinical studies using
the Tsc2
+/- mouse model. There is also some early evi-
dence that TSC tumor preclinical models are relevant to
TSC brain manifestations as several mouse models with
TSC related brain abnormalities (seizures or cognitive
deficits) also had a reduction of disease severity with
rapamycin treatment [67-69].
There is excitement regarding the recent clinical studies
showing that rapamycin treatment causes TSC-related
tumor regression. However, since regression is incom-
plete, and tumors regrow with cessation of treatment
[32-34] there is significant interest in identifying novel
agents for TSC-related tumors to be used either as single
agents or in combination with rapamycin. In this study,
we evaluated three novel drug classes in our Tsc2
-/- sub-
cutaneous tumor model: an enzyme that interferes with
amino acid metabolism (asparaginase), two VEGF inhibi-
tors (sunitinib and bevacizumab), and a microtubule inhi-
bitor (vincristine). These drugs were tested both as single
agents and in combination with rapamycin. We found
that asparaginase, sunitinib, and bevacizumab are effective
as single agents, but not as effective as rapamycin. Vin-
cristine was not effective as a single agent. None of these
drugs combined with rapamycin was more effective than
single agent rapamycin treatment. Based on 24 hour
rapamycin level measurements, there was no evidence
that drug interaction issues influenced the outcome of
rapamycin combination treatment with sunitinib or beva-
cizumab. Rapamycin levels were not tested in the combi-
nation groups with asparaginase or vincristine because of
the dosing schedule used.
Although asparaginase, sunitinib, and bevacizumab
had only a modest improvement (24-27%) in median
survival compared to untreated control groups (p values
= 0.010-0.019), this difference was statistically signifi-
cant. In contrast, the improvement in median survival of
rapamycin treatment was dramatic (173% compared
with untreated, p value = < 0.0001). The positive results
with asparaginase treatment are consistent with the
known influence of amino acid depletion on the TSC1/
TSC2-mTOR signaling pathway [35]. Similarly, the posi-
tive results with sunitinib and bevacizumab are consis-
tent with the known relevance of the VEGF signaling
pathway in TSC related lesions and in vitro studies of
TSC deficient cells [39,40].
There are now several preclinical studies in mouse
models of TSC related tumors that have evaluated the
efficacy of alternatives to mTOR inhibitors as either sin-
gle agents or in combination with an mTOR inhibitor.
Single agent drugs which are FDA approved for other
indications that are effective in mouse TSC tumor mod-
els include interferon gamma (IFN-g), sunitinib, bevaci-
zumab, asparaginase, and tamoxifen. There are also
several drugs in development (so are not FDA approved)
with single agent activity in TSC tumor models; these
include a MEK1/2 inhibitor (CI-1040) [70] and a dual
PI3K/mTOR inhibitor (NVP-BEZ-235) [71]. Drugs for
which combination with mTOR inhibitor treatment is
more effective than single agent mTOR inhibitor include
IFN-g and sorafenib (both are FDA approved for other
indications). In order to evaluate optimal strategies for
future clinical trials for TSC related tumors, we have
reviewed all TSC tumor preclinical studies focusing on
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inhibitors. As many were done using the Tsc2
-/- subcuta-
neous tumor model, we have summarized the results
from this model in Table 4 from this and previous studies
[20,21,31,61]. This summary shows that mTOR inhibitors
are clearly most effective with improvements in median
survival ranging from 52-173%. The combination of IFN-
g plus CCI-779 improved median survival over untreated
by 220% compared with 134% for single agent CCI-779.
The combination of sorafenib plus rapamycin improved
median survival over untreated by 134% compared with
88% for single agent rapamycin. Single agent drug treat-
ment alternatives to mTOR inhibitors improved median
survival from 24-52% (IFN-g, sunitinib, bevacizumab and
asparaginase). Tamoxifen was used to treat Tsc1
+/- mice
(in 129/sv background) and was found to reduce the fre-
quency and severity of liver hemangiomas [72]. It is
encouraging to note that there is limited case report evi-
dence that treatment of TSC related tumors with tamoxi-
fen may also correlate with findings in mouse models.
There is one report of a massive liver angiomyolipoma in
a 26 year old female with TSC2 disease that regressed
after treatment with tamoxifen [73]. The MEK1/2 inhibi-
tor was used to treat estrogen induced tumors derived
from Tsc2-null uterine leiomyoma cells. In this model,
the mTOR inhibitor RAD001 completely blocked both
primary tumor growth and lung metastasis, and a MEK1/
2 inhibitor (CI-1040) inhibited lung metastasis. The
Table 4 Summary of Survival Data for Effective Agents in the Tsc2-/- Subcutaneous Tumor Model
Reference Start Criteria Treatment
Cohort
Dosing Median
Survival
(days)
Percent Difference
From Untreated
Drug
class
Current
Study
Tumor Volume of 100 mm3 Untreated - 31 -
Rapamycin 8 mg/kg 3 days/wk 84.5 173% *
Asparaginase 2IU/g twice/wk × 4 wks 39.5 27% #
Asparaginase +
Rapamycin
2IU/g twice/wk × 4 wks +
8 mg/kg 3 days/wk
71 129%
Sunitinib 80 mg/kg 5 days/wk 39 26% #
Sunitinib +
Rapamycin
80 mg/kg 5 days/wk +
8 mg/kg 3 days/wk
80 158%
Bevacizumab 5 mg/kg once/2 wks 38.5 24% #
Bevacizumab +
Rapamycin
5 mg/kg once/2 wks +
8 mg/kg 3 days/wk
60 94%
Lee et al,
2009
Tumor Volume of 150 mm3 Untreated - 24.5 -
Rapamycin 8 mg/kg 5 days/wk 46 88% *
Sorafenib 60 mg/kg 5 days/wk 19.5 -20%
Sorafenib +
Rapamycin
60 mg/kg 5 days/wk +
8 mg/kg 5 days/wk
53 116% **
Messina
et al, 2007
Tumor Volume of 50 mm3 for early
treatments, 250 mm3 for late treatments
Untreated - 31 -
Early CCI-779 8 mg/kg 5 days/wk 47 52% *
Early
Rapamycin
8 mg/kg 5 days/wk 62 100% *
Late Rapamycin 8 mg/kg 5 days/wk 59 90% *
Lee et al,
2006
Tumor Volume of 300 mm3 Untreated - 17.5 -
CCI-779 8 mg/kg 5 days/wk 41 134% *
IFN-g 20,000 units 3 days/wk 22 26% #
IFN-g + CCI-779 20,000 units 3 days/wk +
8 mg/kg 5 days/wk
56 220% **
Lee et al,
2005
18 Days after injection with Tsc2-/- cells Untreated - 33 -
CCI-779 4 mg/kg 3 days/wk 69 109% *
IFN-g 20,000 units 3 days/wk 50 52% #
* Single agent mTOR inhibitor (all agents and doses were more effective than no treatment)
** Combination containing mTOR inhibitor that was more effective than single agent mTOR inhibitor
# Single agent other than mTOR inhibitor that was more effective than no treatment
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growth but this was not statistically significant and not as
effective as the mTOR inhibitor [70]. The dual PI3K/
mTOR inhibitor (NVP-BEZ-235) was used to treat ENU-
accelerated kidney tumors in the Tsc2
+/- mouse.
Although NVP-BEZ-235 reduced the severity of kidney
d i s e a s et oas i m i l a rd e g r e ea sR A D 0 0 1 ,t h ec o m b i n a t i o n
of RAD001 plus NVP-BEZ-235 was similar to single
agents [71]. There are also several drugs that were not
effective in preclinical models including vincristine, doxy-
cycline, and atorvastatin [61,74].
Conclusions
The preclinical studies reported here show that the A/J
Tsc2
+/- mouse model has younger onset TSC related
kidney disease and as a result, is an improved mouse
model for use in future preclinical studies. Our rapamy-
cin dosing comparison results in A/J Tsc2
+/- mice indi-
cate that a longer duration of rapamycin treatment is
more important than dose intensity, therefore low doses
for a prolonged duration seems to be the best strategy.
Since the response to mTOR inhibitors in Tsc2
+/- mice
correlates well with observations in rapamycin kidney
angiomyolipoma trials, it would be reasonable to test
this dosing strategy in future TSC clinical trials. We also
present data showing evidence for tumor response to
some new single agents including sunitinib, bevacizu-
mab, and asparaginase. We have previously shown that
single agent IFN-g, combination IFN-g plus mTOR inhi-
bitor, and combination sorafenib plus mTOR inhibitor
are effective in the Tsc2
-/- subcutaneous tumor model.
Since tumor responses to mTOR inhibitor treatment are
much more dramatic than responses to other agents
(see Table 4) and combination treatments are only a
slight improvement over single agent mTOR inhibitor
treatment, single agent mTOR inhibitor treatment
seems to be the best initial strategy for medical treat-
ment of problematic TSC related tumors. We conclude
that clinical investigation of non-mTOR inhibitors as
single agents or in combination with an mTOR inhibitor
should be investigated as second line therapy for proble-
matic TSC related tumors that are not responding to
mTOR inhibitors. This work illustrates the clinical rele-
vance of preclinical studies in mouse models of TSC2
related tumors. Future preclinical studies using these
and related mouse models are likely to guide a rational
approach to improving medical therapy for TSC related
tumors and other manifestations of TSC.
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